ストックスクリーナーアプリを入手
25.52
2.56%
-0.67
アフターアワーズ：
25.52
前日終値:
$26.19
開ける：
$26.26
24時間の取引高:
618.12K
Relative Volume:
0.43
時価総額：
$2.25B
収益：
-
当期純損益:
$-151.78M
株価収益率:
-12.39
EPS:
-2.0595
ネットキャッシュフロー:
$-136.42M
1週間 パフォーマンス:
-4.46%
1か月 パフォーマンス:
-5.41%
6か月 パフォーマンス:
-17.38%
1年 パフォーマンス:
+80.35%
1日の値動き範囲:
$25.20
$26.96
1週間の範囲:
$25.20
$28.19
52週間の値動き範囲:
$12.59
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
名前
Mineralys Therapeutics Inc
セクター
電話
(888) 378-6240
住所
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
25.52 | 2.40B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-27 | 開始されました | TD Cowen | Buy |
| 2025-06-11 | 開始されました | Jefferies | Hold |
| 2024-07-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-02 | 開始されました | Goldman | Buy |
| 2023-03-07 | 開始されました | BofA Securities | Buy |
| 2023-03-07 | 開始されました | Credit Suisse | Outperform |
| 2023-03-07 | 開始されました | Evercore ISI | Outperform |
| 2023-03-07 | 開始されました | Guggenheim | Buy |
| 2023-03-07 | 開始されました | Stifel | Buy |
| 2023-03-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Mineralys Therapeutics Inc (MLYS) 最新ニュース
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring an 80% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
New Mineralys hires receive stock awards vesting over four years - Stock Titan
Mineralys Therapeutics Inc (MLYS) Institutional Confidence - TradingKey
Mineralys Therapeutics Inc (MLYS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mineralys Therapeutics Inc (MLYS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mineralys Therapeutics Inc (MLYS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Mineralys Therapeutics Inc (MLYS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mineralys Therapeutics, Inc. Revenue Breakdown – NASDAQ:MLYS - TradingView
MLYS|Mineralys Therapeutics Inc|Price:27.920|Chg%:+1.210 - TradingKey
MLYS|Mineralys Therapeutics Inc|Price:27.856|Chg%:+1.146 - TradingKey
Mineralys Therapeutics Inc (MLYS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mineralys Chief Commercial Officer Eric Warren disposes of $199,900 in common shares - Bitget
Form 4 Mineralys Therapeutics Inc For: 23 July By Investing.com - Investing.com Nigeria
Mineralys Therapeutics CCO Eric Warren sells $199k in shares - Investing.com
Mineralys (NASDAQ: MLYS) CCO sells 7,438 shares after option exercise - Stock Titan
Form 4 Mineralys Therapeutics Inc For: 21 July By Investing.com - Investing.com Australia
Mineralys Therapeutics (MLYS) affiliate plans 7,438-share stock sale after options exercise - Stock Titan
Mineralys Therapeutics CMO David Rodman disposes of $11,036 in shares By Investing.com - Investing.com Nigeria
Mineralys Therapeutics CMO David Rodman disposes of $11,036 in shares - Investing.com
Mineralys Therapeutics, Inc. (MLYS): Analyst Consensus Points to a Promising 83% Upside Potential - DirectorsTalk Interviews
Mineralys CMO David Malcom Rodman disposes of 416 common shares worth $11,036.48 - Bitget
Responsive Playbooks and the MLYS Inflection - Stock Traders Daily
Form 144 Mineralys Therapeutics For: 17 July By Investing.com - Investing.com Nigeria
Mineralys Therapeutics (MLYS) insider schedules 416-share sale after option exercise - Stock Titan
Mineralys Executive Stock Sale Analysis - Intellectia AI
A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date - The Motley Fool
What to Know About This Mineralys Insider Sale Before a December FDA Date - The Motley Fool
Mineralys Therapeutics (MLYS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Mineralys Therapeutics (MLYS) Q3 2025 earnings summary - Quartr
Mineralys therapeutics CMO Rodman sells $556,671 in shares By Investing.com - Investing.com South Africa
Mineralys therapeutics CMO Rodman sells $556,671 in shares - Investing.com UK
Form 4 Mineralys Therapeutics Inc For: 15 July By Investing.com - Investing.com South Africa
Mineralys Therapeutics CEO Jon Congleton sells $291,441 in stock By Investing.com - Investing.com South Africa
Insider Sell: CEO Jon Congleton Sells 10,700 Shares of Mineralys Therapeutics Inc (MLYS) - GuruFocus
Mineralys Therapeutics (MLYS) CMO sells 20,407 shares and exercises options - Stock Titan
Mineralys Therapeutics (MLYS) CEO logs 10,700-share sale under Rule 10b5-1 plan - Stock Titan
Planned 6,349-share stock sale by Mineralys Therapeutics (NASDAQ: MLYS) - Stock Titan
Frontier tech research, news & data - MLQ.ai
Planned 14,058-share sale at Mineralys Therapeutics (NASDAQ: MLYS) - Stock Titan
Form 144 Mineralys Therapeutics For: 13 July By Investing.com - Investing.com Australia
Mineralys Therapeutics (MLYS) insider plans 10,700-share Rule 144 stock sale - Stock Titan
Mineralys Therapeutics (MLYS) insider details stock option exercise and sales - Stock Titan
Number of shareholders of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView
Mineralys Therapeutics Inc (MLYS) 財務データ
収益
当期純利益
現金流量
EPS
Mineralys Therapeutics Inc (MLYS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Warren Eric | Chief Commercial Officer |
Jul 21 '26 |
Sale |
26.87 |
7,438 |
199,885 |
38,400 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):